Previous 10 |
Shares of IO Biotech (IOBT +31.7%), which has been on a roller coaster ride over the last week, are significantly higher today. Trading in the stock was already halted twice this morning due to extraordinary market activity. As of 1013a ET, volume is ~1.4M shares. That compares to a daily ave...
IO Biotech (IOBT +7.9%), which had its IPO earlier this month, has ended its quiet period today with an upward swing. However, shares are still well below the IPO price of $14 a share. IO's lead candidate, IO102-IO103, is in phase 3 in combination with a PD1 monoclonal antibody as a first-lin...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, including the exercise in full by the underwriters’ option to purchase ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and ...